ELOCTA® was the first extended half-life recombinant Factor VIII approved in the EU Learn more Joint protection Find out more Introducing ELOCTA Find out more Why ELOCTA? Find out more Fc-fusion technology explained Sobi’s commitment in Haemophilia ELOCTA® was the first extended half-life recombinant Factor VIII approved in the EU Learn more Joint protection Find out more Introducing ELOCTA Find out more Why ELOCTA? Find out more Fc-fusion technology explained Sobi’s commitment in Haemophilia
